Tuftsin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
== Principle of chiral column chromatography == The chiral stationary phase, CSP, can interact differently with two enantiomers, by a process known as chiral recognition. Chiral recognition depends on various interactions such as hydrogen bonding, π-π interaction, dipole stacking, inclusion complexation, steric, hydrophobic and electrostatic interaction, charge-transfer interactions, ionic interactions etc, between the analyte and the CSP, to form in-situ transient-diastereomeric complexes. Most of the types of stationary phases can be classified as Pirkle type (Brush type), Protein-based, Cyclodextrins based, Polymer-based carbohydrates (polysaccharide-based CSPs), Macrocyclic antibiotic, Chiral crown ethers, imprinted polymers, etc.
In 1896, Viennese dermatologist Leopold Freund (1868-1943) used X-rays to treat patients for the first time. He successfully irradiated the hairy nevus of a young girl. In 1897, Hermann Gocht (1869–1931) published the treatment of trigeminal neuralgia with X-rays, and Alexei Petrovich Sokolov (1854-1928) wrote about radiotherapy for arthritis in the oldest radiology journal, Advances in the field of X-rays (RöFo). In 1922, X-rays were recommended as safe for many diseases and for diagnostic purposes. Radiation protection was limited to recommending doses that would not cause erythema (reddening of the skin). For example, X-rays were promoted as an alternative to tonsillectomy. It was also boasted that in 80% of cases of diphtheria carriers, Corynebacterium diphtheriae was no longer detectable within two to four days. In the 1930s, Günther von Pannewitz (1900–1966), a radiologist from Freiburg, Germany, perfected what he called X-ray stimulation radiation for degenerative diseases. Low-dose radiation reduces the inflammatory response of tissues. Until about 1960, children with diseases such as ankylosing spondylitis or favus (head fungus) were irradiated, which was effective but led to increased cancer rates among patients decades later. In 1926, the American pathologist James Ewing (1866-1943) was the first to observe bone changes as a result of radiotherapy, which he described as radiation osteitis (now Osteoradionecrosis). In 1983, Robert E. Marx stated that osteoradionecrosis is radiation-induced aseptic bone necrosis.
== History == Opioid peptides in the brain were first discovered in 1973 by investigators at the University of Aberdeen, John Hughes and Hans Kosterlitz. They isolated "enkephalins" (from the Greek εγκέφαλος) from pig brain, identified as met-enkephalin and leu-enkephalin. This came after the discovery of a receptor that was proposed to produce the pain-relieving analgesic effects of morphine and other opioids, which led Kosterlitz and Hughes to their discovery of the endogenous opioid ligands. Research during this time was focused on the search for a painkiller that did not have the addictive character or overdose risk of morphine. Rabi Simantov and Solomon H. Snyder isolated morphine-like peptides from calf brain. Eric J. Simon, who independently discovered opioid receptors, later termed these peptides as endorphins. This term was essentially assigned to any peptide that demonstrated morphine-like activity. In 1976, Choh Hao Li and David Chung recorded the sequences of α-, β-, and γ-endorphin isolated from camel pituitary glands for their opioidergic activity. Li determined that β-endorphin produced strong analgesic effects. Wilhelm Feldberg and Derek George Smyth in 1977 confirmed this, finding β-endorphin to be more potent than morphine. They also confirmed that its effects were reversed by naloxone, an opioid antagonist. Studies have subsequently distinguished between enkephalins, endorphins, and endogenously produced true morphine, which is not a peptide.
=== Challenges === The stigma surrounding addiction can heavily influence opioid addicts not to seek help. Stigma may arise from a variety of sources, including friends, family, employers, and healthcare providers. People who experience stigma related to their opioid use disorder are less inclined to seek out treatment or remain in treatment because of shame or feelings of being judged. Therefore, reducing stigma via education and support improves outcomes in the treatment of OUD and makes people more confident in seeking treatment. Many people view addiction as a moral failing rather than a medical condition, which can lead to feelings of shame and isolation. This stigma can affect family members, making it difficult for them to support their loved ones effectively. According to position papers on the treatment of opioid dependence published by the United Nations Office on Drugs and Crime and the World Health Organization, care providers should not treat opioid use disorder as the result of a weak moral character or will but as a medical condition. Some evidence suggests the possibility that opioid use disorders occur due to genetic or other chemical mechanisms that may be difficult to identify or change, such as dysregulation of brain circuitry involving reward and volitional experience. It has also been hypothesized that endocrine and autonomic nervous system abnormalities can be opioid-induced. Critically, the endogenous opioid system is involved in reward; changes to this system affect experience and subsequent behavior.
Sources: en.wikipedia.org
A cessation of hostilities beginning on 16 April 2026 at 17:00 EST for an initial period of ten days, intended to enable negotiations toward a permanent agreement. The possibility of extending the ceasefire by mutual agreement if progress is made in negotiations and Lebanon demonstrates effective sovereignty. Israel retains the right to act in self-defense against imminent or ongoing threats, while refraining from offensive military operations in Lebanon. Lebanon, with international support, is to take steps to prevent Hezbollah and other non-state armed groups from carrying out attacks against Israel. Recognition of the Lebanese state's security forces as solely responsible for national sovereignty and defense. A request for the United States to facilitate further direct negotiations, including on border demarcation and a comprehensive peace agreement. Hezbollah was not a formal signatory to the agreement, despite being a principal party in the fighting.
=== Colony forming unit – Hill === As originally isolated by Asahara et al., the CFU-Hill population is an early outgrowth, formed by plating peripheral blood mononuclear cells on fibronectin-coated dishes, allowing adhesion and depleting non-adherent cells, and isolating discrete colonies.
==== Chlorine dioxide ==== Chlorine dioxide can come from tablets or be created by mixing two chemicals together. It is more effective than iodine or chlorine against giardia, and although it has only low to moderate effectiveness against cryptosporidium, iodine and chlorine are ineffective against this protozoan. The cost of chlorine dioxide treatment is higher than the cost of iodine treatment.
== Research == More than 160 faculty members at the University of Texas Health Science Center at San Antonio are actively involved in biomedical and clinical research and educational activities that range from the molecular genetics of aging to issues of health care for the elderly population. Research at the Barshop Institute spans the continuum from basic discovery science to translational and clinical research aimed at extending healthspan and improving quality of life in older adults. Investigators study the fundamental biological processes that drive aging—including cellular senescence, mitochondrial dysfunction, metabolism, inflammation, genomic instability, and impaired tissue regeneration—and apply these discoveries to develop strategies for preventing or treating age-related diseases. Major areas of investigation include Alzheimer's disease and related dementias, cardiovascular disease, type 2 diabetes and metabolic disorders, cancer, frailty, sarcopenia, osteoporosis, and age-associated liver disease. Through the integration of laboratory research, animal models, clinical trials, and population-based studies, Barshop Institute scientists are advancing new therapeutic approaches that target the underlying mechanisms of aging to delay the onset of chronic disease, preserve physical and cognitive function, and promote healthy longevity.
1938: American botanists Elzada U Clover and Lois Jotter were the first women to catalog plant life in the Grand Canyon and the first to raft the entire length of the Colorado River 1939: Austrian-Swedish physicist Lise Meitner, along with Otto Hahn, led the small group of scientists who first discovered nuclear fission of uranium when it absorbed an extra neutron; the results were published in early 1939. 1939: French physicist Marguerite Perey discovered the chemical element francium. 1939: Indian biochemist Kamala Sohonie became the first Indian woman to receive a PhD in a scientific discipline in 1939.
Sources: en.wikipedia.org
In Chinese, the most commonly used names are fěnsī (Chinese: 粉絲; lit. 'noodle thread') and fěntiáo or hóngshǔfěn (Chinese: 粉條 or Chinese: 紅薯粉; lit. 'noodle strip' or 'sweet potato noodles'). They are also marketed under the name saifun, the Cantonese pronunciation of the Mandarin xìfěn (Chinese: 細粉; lit. 'slender noodle', though the name fánsī (粉絲) is the term most often used in Cantonese. In China, glass noodles are a popular ingredient used in stir-fries, soups, and particularly hot pots. They can also be used as an ingredient in fillings for a variety of Chinese jiaozi (dumplings) and bing (flatbreads), especially in vegetarian versions of these dishes. Thicker glass noodles are also commonly used to imitate the appearance and texture of shark's fin in vegetarian soups. Thicker varieties, most popular in China's northeast, are used in stir-fries as well as cold salad-like dishes. A popular Shanghai cuisine using the ingredient is fried tofu with thin noodles (Chinese: 油豆腐線粉湯; pinyin: yóu dòu fu-xiàn fěn tāng). A popular Sichuan dish called "ants climbing a tree" consists of stewed glass noodles with a spicy ground pork meat sauce. In Tibetan cuisine, glass noodles are called phing or fing and are used in soup, in pork curry, or with mushrooms.
These pathways are also important in environmental science, with the xenobiotic metabolism of microorganisms determining whether a pollutant will be broken down during bioremediation, or persist in the environment. The enzymes of xenobiotic metabolism, particularly the glutathione S-transferases are also important in agriculture, since they may produce resistance to pesticides and herbicides.
=== Serotonin precursors === The serotonin precursors tryptophan and 5-hydroxytryptophan (5-HTP; oxitriptan) are available as over-the-counter supplements. They are often used to produce sleepiness and treat insomnia. However, little to no clinical data exist to support their use or effectiveness.
=== Inhibitor of mitochondrial permeability transition pore === It has also been shown that the compound inhibits mitochondrial permeability transition pore (MPTP) by inhibiting the activity of the pore regulator, cyclophilin D (CyP-D). CyP-D is a peptidyl-prolyl cis-trans isomerase or protein that causes a proline residue in a peptide to switch from its trans isomer to its cis isomer. Studies have been done using the Calcium retention capacity (CRC) assay on mouse liver mitochondria in order to measure antamanide's effect on the permeability transition pore. The data from this experiment showed that antamanide inhibits pore opening like the known inhibitors CsA and Ubiquinone 0. It has been found that altering the 6 and 9 positions in the cyclic peptide ring disables the inhibitory effect on the pore by the drug. A study has also been to determine whether the antamanide also inhibits the apoptosis (programmed cell death) of human cervical carcinoma cells caused by the permeability transition pore. The results showed an inhibitory response. Studying for inhibitors of MPTP is important because MPTP induction is connected to many diseases, such as muscular dystrophies (a disease that weakens the musculoskeletal system), hepatotoxicity (chemical caused liver damage), and ischemic injury of the kidneys (injury causing restriction of blood supply to the kidneys).
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.